Clinical Trials Browser

OTHER × Trastuzumab × Gynecologic × Clear all

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT05143970 2024-03-20

CHANCES

Phase 1 Unknown

27 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT01367002 2023-05-17

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Phase 2 Completed

61 enrolled 13 charts

Gynecologic

Endometrial Neoplasms

NCT00433407 2012-10-04

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Phase NA Completed

12 enrolled

BreastGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT00189579 2007-08-17

Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer

Phase 2 Terminated

45 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

Clinical Trials

DETERMINE

CHANCES

SMMART Adaptive Clinical Treatment (ACT) Trial

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer